Fig. 1.
(A) Total inositol phosphate (InsP) production was assessed in Ishikawa WT or FPS cells treated with increasing doses of PGE2 or PGF2α for 1 h at 37 °C. (B) Total InsP production in FPS cells treated with increasing doses of PGE2 or PGF2α in the absence or presence of 50 μM of the specific FP receptor antagonist AL8810 for 1 h at 37 °C. (C) Total InsP production in FPS cells treated with 100 nM PGE2 or 100 nM PGF2α in the absence/presence of the FP receptor antagonist AL8810 (50 μM), EP2 receptor antagonist (AH6809; 10 μM), EP4 receptor antagonist (ONOAE2227; 1 μM) or chemical inhibitors of phospholipase Cβ (U73122, 10 μM), protein kinase A (4C3MQ, 1 μM), protein kinase C (GF109203x, 10 μM) or ERK1/2 kinase (PD98059, 50 μM) for 1 h at 37 °C. Data are presented as mean ± S.E.M. b is significantly different from a, c is significantly different from a and b; P < 0.05.